Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

doi:10.3389/fimmu.2024.1348852

科研成果详情

题名	Opportunities and challenges for anti-CD47 antibodies in hematological malignancies
作者	Xu, Yilan1; Jiang, Panruo 2; Xu, Zhenyan1; Ye, Haige1
发表日期	2024-02-23
发表期刊	FRONTIERS IN IMMUNOLOGY 影响因子和分区
语种	英语
原始文献类型	Review ; Journal Article
关键词	cd47 anti-CD47 antibody immunotherapy hematological malignancies magrolimab
其他关键词	INTEGRIN-ASSOCIATED PROTEIN ; I DOSE-ESCALATION ; MYELODYSPLASTIC SYNDROMES ; AZACITIDINE AZA ; COMBINATION ; MAGROLIMAB ; RITUXIMAB ; CANCER ; CD47 ; EXPRESSION
摘要	CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRP alpha on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRP alpha axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRP alpha/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies.
资助项目	Natural Science Foundation of Zhejiang Province10.13039/501100004731
出版者	FRONTIERS MEDIA SA
ISSN	1664-3224
卷号	15
DOI	10.3389/fimmu.2024.1348852
页数	11
WOS类目	Immunology
WOS研究方向	Immunology
WOS记录号	WOS:001177015100001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	3846452
通讯作者地址	[Ye, Haige]Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/209923
专题	附属第一医院_血液内科
通讯作者	Ye, Haige
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou, Peoples R China; 2.Dongyang Peoples Hosp, Dept Hematol, Jinhua, Peoples R China
第一作者单位	附属第一医院_血液内科
通讯作者单位	附属第一医院_血液内科
第一作者的第一单位	附属第一医院_血液内科
推荐引用方式 GB/T 7714	Xu, Yilan,Jiang, Panruo,Xu, Zhenyan,et al. Opportunities and challenges for anti-CD47 antibodies in hematological malignancies[J]. FRONTIERS IN IMMUNOLOGY,2024,15.
APA	Xu, Yilan, Jiang, Panruo, Xu, Zhenyan, & Ye, Haige. (2024). Opportunities and challenges for anti-CD47 antibodies in hematological malignancies. FRONTIERS IN IMMUNOLOGY, 15.
MLA	Xu, Yilan,et al."Opportunities and challenges for anti-CD47 antibodies in hematological malignancies".FRONTIERS IN IMMUNOLOGY 15(2024).